Tag Archives: ARQL

Top 10 Tech Stocks To Watch For 2019

Biotech stocks sometimes have a stigma of being highly speculative and highly risky. But several large biotech stocks generate impressive cash flow and have promising growth prospects. And they’re not all priced for perfection, either.

We asked three Motley Fool contributors to weigh in on which biotech stocks they like. Here’s why they chose Celgene (NASDAQ:CELG), Exelixis (NASDAQ:EXEL),....More>>>

Top 10 Biotech Stocks To Own For 2019

Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) from a sell rating to a hold rating in a research report report published on Friday.

According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory....More>>>

Best Biotech Stocks To Watch Right Now

Krystal Biotech (NASDAQ:KRYS) and Coherus Biosciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Insider & Institutional Ownership

Get Krystal Biotech alerts:....More>>>

Best Insurance Stocks To Invest In 2019

RenaissanceRe Holdings Ltd (NYSE:RNR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. RenaissanceRe Holdings Ltd is a provider of insurance products. Its portfolio encompasses property catastrophe and specialty reinsurance risks. RenaissanceRe Holdings Ltd has a market cap of $5.74 billion; its shares were traded at around $142.65 with a P/E ratio of 29.02 and P/S....More>>>

Top 5 Biotech Stocks For 2019

NanoString Technologies Inc (NASDAQ:NSTG) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. NanoString Technologies Inc is a biotechnology company. It develops, manufactures and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. NanoString Technologies Inc has a market cap of $916.930 million;....More>>>

Top Blue Chip Stocks To Invest In 2019

U.S. stocks opened firmly higher on Thursday, extending a late-session rally from the prior session, as investors dialed back on fears that a trade spat between the U.S. and China will materialize.

The major equity indexes staged a big turnaround Wednesday after opening sharply lower, as traders struggled to interpret the possible impact of the trade standoff on U.S. corporate earnings and....More>>>

Top Biotech Stocks To Buy Right Now

Trexquant Investment LP raised its stake in shares of ImmunoGen (NASDAQ:IMGN) by 190.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,215 shares of the biotechnology company’s stock after buying an additional 217,244 shares during the quarter. Trexquant Investment LP owned about 0.25% of ImmunoGen worth $3,484,000....More>>>

Hot Biotech Stocks To Buy For 2019

What happened

Shares of Verastem (NASDAQ:VSTM) are up 16% in late-day trading on Friday after the company announced yesterday after the bell that it was selling 7,166,666 shares at $6 per share, grossing the biotech approximately $43 million.

So what

Share prices typically — though clearly not always — go down after a secondary offering is announced, since current....More>>>

Top 10 Biotech Stocks To Own For 2019

Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,931 shares of the biotechnology company’s stock, valued at approximately $100,000.

Several other large investors also recently added....More>>>

Top 5 Biotech Stocks For 2019

What happened

Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”

Image source: Getty Images.

So what

In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>

Hot Biotech Stocks To Own For 2019

The meteoric run up in cryptocurrency valuations last year looked every bit a speculative bubble as the dot-com craze 20 years ago, and the subsequent implosion of valuations in the months since has deepened the parallels. A recent Bloomberg story noted that hundreds of virtual coins have gone to practically zero in value as the market crashed.

Although some tokens will continue to offer....More>>>

Top Biotech Stocks To Own Right Now

The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.

As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies.....More>>>

Hot Biotech Stocks To Buy Right Now

Fluidigm (NASDAQ:FLDM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD....More>>>

Best Biotech Stocks To Own For 2019

Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!

So what’s in store for today?

BioMarin makes itself a priority to the FDA in phenylketonuria

Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>

Best Biotech Stocks To Buy Right Now


Before explaining and updating my version of the Celgene (NASDAQ:CELG) story, first, I’ll briefly explain and link to the 2 1/2-year story of my bullish-bearish-bullish evolution of views on this stock. This will help lay the groundwork to why I am again accentuating the positives, understanding there are negatives; the article goes into both sides of the CELG argument.